142 related articles for article (PubMed ID: 12824033)
1. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
Kim E; Chun HO; Jung SH; Kim JH; Lee JM; Suh BC; Xiang MX; Rhee CK
Bioorg Med Chem Lett; 2003 Jul; 13(14):2355-8. PubMed ID: 12824033
[TBL] [Abstract][Full Text] [Related]
2. Aryl sulfonamides as selective PDE4 inhibitors.
Montana JG; Buckley GM; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Miotla J; Naylor RJ; Runcie KA; Tuladhar B; Warneck JB
Bioorg Med Chem Lett; 1998 Oct; 8(19):2635-40. PubMed ID: 9873594
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
4. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
[TBL] [Abstract][Full Text] [Related]
5. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.
Christensen SB; Guider A; Forster CJ; Gleason JG; Bender PE; Karpinski JM; DeWolf WE; Barnette MS; Underwood DC; Griswold DE; Cieslinski LB; Burman M; Bochnowicz S; Osborn RR; Manning CD; Grous M; Hillegas LM; Bartus JO; Ryan MD; Eggleston DS; Haltiwanger RC; Torphy TJ
J Med Chem; 1998 Mar; 41(6):821-35. PubMed ID: 9526558
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294.
Gale DD; Hofer P; Spina D; Seeds EA; Banner KH; Harrison S; Douglas G; Matsumoto T; Page CP; Wong RH; Jordan S; Smith F; Banik N; Halushka PV; Cavalla D; Rotshteyn Y; Kyle DJ; Burch RM; Chasin M
Pulm Pharmacol Ther; 2003; 16(2):97-104. PubMed ID: 12670778
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
8. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
[TBL] [Abstract][Full Text] [Related]
9. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Ohmachi Y; Kikkawa H; Ikezawa K; Naito K
J Med Chem; 1999 Mar; 42(6):1088-99. PubMed ID: 10090791
[TBL] [Abstract][Full Text] [Related]
10. Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret.
Duplantier AJ; Biggers MS; Chambers RJ; Cheng JB; Cooper K; Damon DB; Eggler JF; Kraus KG; Marfat A; Masamune H; Pillar JS; Shirley JT; Umland JP; Watson JW
J Med Chem; 1996 Jan; 39(1):120-5. PubMed ID: 8568798
[TBL] [Abstract][Full Text] [Related]
11. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
[TBL] [Abstract][Full Text] [Related]
12. PDE4 inhibitors: new xanthine analogues.
Montana JG; Cooper N; Dyke HJ; Gowers L; Gregory JP; Hellewell PG; Miotla J; Morris K; Naylor R; Tuladhar B; Warneck JB
Bioorg Med Chem Lett; 1998 Oct; 8(20):2925-30. PubMed ID: 9873649
[TBL] [Abstract][Full Text] [Related]
13. N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
Bacher E; Boer C; Bray-French K; Demnitz FW; Keller TH; Mazzoni L; Müller T; Walker C
Bioorg Med Chem Lett; 1998 Nov; 8(22):3229-34. PubMed ID: 9873708
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
Beasley SC; Cooper N; Gowers L; Gregory JP; Haughan AF; Hellewell PG; Macari D; Miotla J; Montana JG; Morgan T; Naylor R; Runcie KA; Tuladhar B; Warneck JB
Bioorg Med Chem Lett; 1998 Oct; 8(19):2629-34. PubMed ID: 9873593
[TBL] [Abstract][Full Text] [Related]
16. 8-Methoxyquinoline-5-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Buckley GM; Cooper N; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Oxford J; Peake JC; Picken CL; Runcie KA; Sabin V; Sharpe A; Warneck JB
Bioorg Med Chem Lett; 2002 Jun; 12(12):1613-5. PubMed ID: 12039574
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new orally active phosphodiesterase (PDE4) inhibitors.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1098-104. PubMed ID: 15340197
[TBL] [Abstract][Full Text] [Related]
18. KF19514, a phosphodieterase 4 and 1 inhibitor, inhibits PAF-induced lung inflammatory responses by inhaled administration in guinea pigs.
Manabe H; Akuta K; Okamura K; Ohmori K
Int Arch Allergy Immunol; 1997 Dec; 114(4):389-99. PubMed ID: 9414145
[TBL] [Abstract][Full Text] [Related]
19. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
20. Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.
Turner NC; Lamb J; Worby A; Murray KJ
Br J Pharmacol; 1994 Apr; 111(4):1047-52. PubMed ID: 8032589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
